Research graph
References from Medical issues and pulmonary outcomes in cystic fibrosis and bronchiectasis. Local targets link to admitted publications; unresolved targets remain external evidence.
Pathophysiology of bronchiectasis
10.1055/s-0041-1730891 · 2021 · External reference
Cystic fibrosis: a review
10.1001/jama.2023.8120 · 2023 · External reference
Bronchiectasis: a clinical review of inflammation
10.1016/j.rmed.2025.108179 · 2025 · External reference
Inflammation: a two-edged sword--the model of bronchiectasis
1986 · External reference
Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020
10.1016/j.jcf.2023.02.009 · 2023 · External reference
Increasing life expectancy in cystic fibrosis: advances and challenges
2022 · External reference
Epidemiology of bronchiectasis
10.1183/16000617.0091-2024 · 2024 · External reference
Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: Data from the UK CF registry
10.1016/j.jcf.2020.04.008 · 2021 · External reference
Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis
10.1016/j.jcf.2022.12.009 · 2023 · External reference
Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis
10.1016/j.cmi.2020.04.007 · 2021 · External reference
EPS6.05 Clinical outcomes in concurrent elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treated vs. ineligible cohorts in the US Cystic Fibrosis Foundation Patient Registry (CFFPR) during COVID-19
10.1016/s1569-1993(24)00264-9 · 2024 · External reference
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis
10.1183/13993003.01953-2017 · 2018 · External reference
Endotypes of Pseudomonas aeruginosa infection in bronchiectasis are associated with inhaled antibiotic response: results from two randomized, double-blind, placebo-controlled phase III Trials (ORBIT 3 and ORBIT 4)
10.1164/rccm.202501-0159oc · 2025 · External reference
The contribution of carbapenem-resistant Pseudomonas Aeruginosa isolation to clinical outcomes in hospitalized patients with exacerbations of bronchiectasis: a retrospective cohort study
10.1007/s00408-024-00770-7 · 2025 · External reference
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
10.1016/s2213-2600(23)00093-0 · 2023 · External reference
Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France
10.1128/jcm.01257-09 · 2009 · External reference
Nontuberculous mycobacteria in cystic fibrosis and noncystic fibrosis bronchiectasis
10.1055/s-0035-1546751 · 2015 · External reference
Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry
10.1016/j.chest.2016.10.055 · 2017 · External reference
Nontuberculous mycobacteria in cystic fibrosis
10.1007/s40506-016-0092-6 · 2016 · External reference
Treatment outcomes of nontuberculous mycobacterial infection in the Danish Cystic Fibrosis Cohort
10.1016/j.jcf.2025.12.008 · 2026 · External reference
Sinonasal disease among patients with primary ciliary dyskinesia: an international study
10.1183/23120541.00701-2022 · 2023 · External reference
Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review
10.1002/alr.21789 · 2016 · External reference
Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease
10.1513/annalsats.201401-044fr · 2014 · External reference
Effects of gastro-oesophageal reflux and pulmonary micro-aspiration in bronchiectasis
External reference
Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease
10.1016/j.chest.2022.08.2228 · 2023 · External reference
Prevalence and clinical implications of bronchiectasis in patients with overlapping asthma and chronic rhinosinusitis: a single-center prospective study
10.1186/s12890-021-01575-7 · 2021 · External reference
The phenotypes of asthma-bronchiectasis overlap: clinical characteristics and outcomes
10.4168/aair.2025.17.2.196 · 2025 · External reference
Allergic bronchopulmonary aspergillosis and Aspergillus-related airway diseases in bronchiectasis: a narrative review
10.21037/jtd-2025-1548 · 2025 · External reference
Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity
10.1513/annalsats.201507-472oc · 2015 · External reference
Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis
10.1016/j.semarthrit.2021.08.005 · 2021 · External reference
Systemic sclerosis and risk of bronchiectasis: a nationwide longitudinal cohort study
10.1186/s13075-023-03189-2 · 2023 · External reference
Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries
10.1016/s2213-2600(26)00057-3 · 2026 · External reference
Cystic Fibrosis-Related Diabetes (CFRD): overview of associated genetic factors
10.3390/diagnostics11030572 · 2021 · External reference
Bone disease in non-cystic fibrosis bronchiectasis: connections, mechanisms, and care gaps
10.1016/j.chest.2026.05.034 · 2026 · External reference
Cystic fibrosis-related bone disease: insights into a growing problem
10.1097/01.med.0000436191.87727.ec · 2013 · External reference
Diagnosis and management of hemoptysis
10.5152/dir.2014.13426 · 2014 · External reference
A systematic approach to the management of massive hemoptysis
10.21037/jtd.2017.06.41 · 2017 · External reference
Which is the best way to treat massive hemoptysis? A systematic review and meta-analysis of observational studies
10.3390/jpm13121649 · 2023 · External reference
Pneumothorax in cystic fibrosis
2014 · External reference
Managing spontaneous pneumothorax in pseudomonas-induced noncystic fibrosis bronchiectasis: the role of video-assisted thoracoscopic surgery and pleurodesis
10.1016/j.chest.2025.07.130 · 2025 · External reference
Pneumothorax in cystic fibrosis
10.1378/chest.123.1.217 · 2003 · External reference
Pneumothorax in cystic fibrosis: a retrospective case series
10.1136/adc.2006.095083 · 2006 · External reference
Pulmonary vascular resistance predicts the mortality in patients with bronchiectasis-associated pulmonary hypertension
10.1097/hjh.0000000000003782 · 2024 · External reference
Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment
10.1183/09031936.95.08060954 · 1995 · External reference
Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis
2008 · External reference
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I
10.1378/chest.113.5.1329 · 1998 · External reference
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis
10.1183/13993003.01126-2025 · 2025 · External reference
The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis
10.1016/j.chest.2024.01.045 · 2024 · External reference
Mucus clearance and lung function in cystic fibrosis with hypertonic saline
10.1056/nejmoa043891 · 2006 · External reference
Hypertonic saline in noncystic fibrosis bronchiectasis (Hyper-BRONCHI): an updated systematic review and meta-analysis
10.1186/s12890-026-04176-4 · 2026 · External reference
Hypertonic saline or carbocisteine in bronchiectasis
10.1056/nejmoa2510095 · 2025 · External reference
Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of noncystic fibrosis bronchiectasis
10.1378/chest.12-1763 · 2013 · External reference
Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis
10.1056/nejmoa2411664 · 2025 · External reference
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial
10.1164/rccm.202108-1986oc · 2022 · External reference
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
10.1016/s2213-2600(24)00411-9 · 2025 · External reference
Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews
2019 · External reference
Airway clearance techniques in bronchiectasis: analysis from the United States Bronchiectasis and non-TB Mycobacteria Research Registry
10.1016/j.chest.2020.06.050 · 2020 · External reference
British Thoracic Society Guideline for bronchiectasis in adults
2019 · External reference
Effects of long-term use of macrolides in patients with noncystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials
10.1186/s12879-015-0872-5 · 2015 · External reference
Azithromycin for prevention of exacerbations in noncystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(12)60953-2 · 2012 · External reference
Effect of azithromycin maintenance treatment on infectious exacerbations among patients with noncystic fibrosis bronchiectasis: the BAT randomized controlled trial
10.1001/jama.2013.1937 · 2013 · External reference
Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with noncystic fibrosis bronchiectasis: the BLESS randomized controlled trial
10.1001/jama.2013.2290 · 2013 · External reference
Physiologic endpoints for clinical studies for cystic fibrosis
10.1016/j.jcf.2016.05.014 · 2016 · External reference
Development and electronic validation of the revised Cystic Fibrosis Questionnaire (CFQ-R Teen/Adult): new tool for monitoring psychosocial health in CF
10.1016/j.jcf.2017.10.015 · 2018 · External reference
Association between bronchiectasis exacerbations and longitudinal changes in FEV1 in patients from the US bronchiectasis and NTM research registry
10.1016/j.rmed.2024.107660 · 2024 · External reference
Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations
10.1016/j.jcf.2017.04.003 · 2017 · External reference
Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)
10.1016/j.jcf.2019.05.009 · 2019 · External reference
Validation of the St. George's Respiratory Questionnaire in bronchiectasis
10.1164/ajrccm.156.2.9607083 · 1997 · External reference
Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores
10.1136/thoraxjnl-2014-205918 · 2015 · External reference
Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
10.1186/s12931-019-1272-y · 2020 · External reference
The bronchiectasis severity index. An international derivation and validation study
10.1164/rccm.201309-1575oc · 2014 · External reference
Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
10.2147/copd.s121943 · 2017 · External reference
Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis
10.1042/bsr20194514 · 2020 · External reference
Predictive value of the modified Bhalla score for assessment of pulmonary exacerbations in adults with cystic fibrosis
10.1007/s00330-020-07095-y · 2021 · External reference
Correlating Reiff scores with clinical, functional, and prognostic factors: characterizing noncystic fibrosis bronchiectasis severity: validation from a nationwide multicenter study in Taiwan
10.1186/s40001-024-01870-z · 2024 · External reference
PRAGMA-CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis
10.1164/rccm.201501-0061oc · 2015 · External reference
Proton MRI assessment of lung structure and function in people with cystic fibrosis
2021 · External reference
Lung abnormalities detected with hyperpolarized 129Xe MRI in patients with long COVID
10.1148/radiol.220069 · 2022 · External reference
Effect of azithromycin maintenance treatment on infectious exacerbations among patients with noncystic fibrosis bronchiectasis: the BAT randomized controlled trial
10.1001/jama.2013.1937 · ExternalCitation · doi-reference
Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with noncystic fibrosis bronchiectasis: the BLESS randomized controlled trial
10.1001/jama.2013.2290 · ExternalCitation · doi-reference
Cystic fibrosis: a review
10.1001/jama.2023.8120 · ExternalCitation · doi-reference
Primary immunodeficiency and recalcitrant chronic sinusitis: a systematic review
10.1002/alr.21789 · ExternalCitation · doi-reference
Predictive value of the modified Bhalla score for assessment of pulmonary exacerbations in adults with cystic fibrosis
10.1007/s00330-020-07095-y · ExternalCitation · doi-reference
The contribution of carbapenem-resistant Pseudomonas Aeruginosa isolation to clinical outcomes in hospitalized patients with exacerbations of bronchiectasis: a retrospective cohort study
10.1007/s00408-024-00770-7 · ExternalCitation · doi-reference
Nontuberculous mycobacteria in cystic fibrosis
10.1007/s40506-016-0092-6 · ExternalCitation · doi-reference
Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry
10.1016/j.chest.2016.10.055 · ExternalCitation · doi-reference
Airway clearance techniques in bronchiectasis: analysis from the United States Bronchiectasis and non-TB Mycobacteria Research Registry
10.1016/j.chest.2020.06.050 · ExternalCitation · doi-reference
Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease
10.1016/j.chest.2022.08.2228 · ExternalCitation · doi-reference
The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis
10.1016/j.chest.2024.01.045 · ExternalCitation · doi-reference
Managing spontaneous pneumothorax in pseudomonas-induced noncystic fibrosis bronchiectasis: the role of video-assisted thoracoscopic surgery and pleurodesis
10.1016/j.chest.2025.07.130 · ExternalCitation · doi-reference
Bone disease in non-cystic fibrosis bronchiectasis: connections, mechanisms, and care gaps
10.1016/j.chest.2026.05.034 · ExternalCitation · doi-reference
Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis
10.1016/j.cmi.2020.04.007 · ExternalCitation · doi-reference
Physiologic endpoints for clinical studies for cystic fibrosis
10.1016/j.jcf.2016.05.014 · ExternalCitation · doi-reference
Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations
10.1016/j.jcf.2017.04.003 · ExternalCitation · doi-reference
Development and electronic validation of the revised Cystic Fibrosis Questionnaire (CFQ-R Teen/Adult): new tool for monitoring psychosocial health in CF
10.1016/j.jcf.2017.10.015 · ExternalCitation · doi-reference
Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS)
10.1016/j.jcf.2019.05.009 · ExternalCitation · doi-reference
Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: Data from the UK CF registry
10.1016/j.jcf.2020.04.008 · ExternalCitation · doi-reference
Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis
10.1016/j.jcf.2022.12.009 · ExternalCitation · doi-reference
Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020
10.1016/j.jcf.2023.02.009 · ExternalCitation · doi-reference
Treatment outcomes of nontuberculous mycobacterial infection in the Danish Cystic Fibrosis Cohort
10.1016/j.jcf.2025.12.008 · ExternalCitation · doi-reference
Association between bronchiectasis exacerbations and longitudinal changes in FEV1 in patients from the US bronchiectasis and NTM research registry
10.1016/j.rmed.2024.107660 · ExternalCitation · doi-reference
Bronchiectasis: a clinical review of inflammation
10.1016/j.rmed.2025.108179 · ExternalCitation · doi-reference
Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis
10.1016/j.semarthrit.2021.08.005 · ExternalCitation · doi-reference
Azithromycin for prevention of exacerbations in noncystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(12)60953-2 · ExternalCitation · doi-reference
EPS6.05 Clinical outcomes in concurrent elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) treated vs. ineligible cohorts in the US Cystic Fibrosis Foundation Patient Registry (CFFPR) during COVID-19
10.1016/s1569-1993(24)00264-9 · ExternalCitation · doi-reference
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
10.1016/s2213-2600(23)00093-0 · ExternalCitation · doi-reference
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
10.1016/s2213-2600(24)00411-9 · ExternalCitation · doi-reference
Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries
10.1016/s2213-2600(26)00057-3 · ExternalCitation · doi-reference
Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis
10.1042/bsr20194514 · ExternalCitation · doi-reference
Nontuberculous mycobacteria in cystic fibrosis and noncystic fibrosis bronchiectasis
10.1055/s-0035-1546751 · ExternalCitation · doi-reference
Pathophysiology of bronchiectasis
10.1055/s-0041-1730891 · ExternalCitation · doi-reference
Mucus clearance and lung function in cystic fibrosis with hypertonic saline
10.1056/nejmoa043891 · ExternalCitation · doi-reference
Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis
10.1056/nejmoa2411664 · ExternalCitation · doi-reference
Hypertonic saline or carbocisteine in bronchiectasis
10.1056/nejmoa2510095 · ExternalCitation · doi-reference
Cystic fibrosis-related bone disease: insights into a growing problem
10.1097/01.med.0000436191.87727.ec · ExternalCitation · doi-reference
Pulmonary vascular resistance predicts the mortality in patients with bronchiectasis-associated pulmonary hypertension
10.1097/hjh.0000000000003782 · ExternalCitation · doi-reference
Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France
10.1128/jcm.01257-09 · ExternalCitation · doi-reference
Pneumothorax in cystic fibrosis: a retrospective case series
10.1136/adc.2006.095083 · ExternalCitation · doi-reference
Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores
10.1136/thoraxjnl-2014-205918 · ExternalCitation · doi-reference
Lung abnormalities detected with hyperpolarized 129Xe MRI in patients with long COVID
10.1148/radiol.220069 · ExternalCitation · doi-reference
Validation of the St. George's Respiratory Questionnaire in bronchiectasis
10.1164/ajrccm.156.2.9607083 · ExternalCitation · doi-reference
The bronchiectasis severity index. An international derivation and validation study
10.1164/rccm.201309-1575oc · ExternalCitation · doi-reference
PRAGMA-CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis
10.1164/rccm.201501-0061oc · ExternalCitation · doi-reference
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial
10.1164/rccm.202108-1986oc · ExternalCitation · doi-reference
Endotypes of Pseudomonas aeruginosa infection in bronchiectasis are associated with inhaled antibiotic response: results from two randomized, double-blind, placebo-controlled phase III Trials (ORBIT 3 and ORBIT 4)
10.1164/rccm.202501-0159oc · ExternalCitation · doi-reference
Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment
10.1183/09031936.95.08060954 · ExternalCitation · doi-reference
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis
10.1183/13993003.01126-2025 · ExternalCitation · doi-reference
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis
10.1183/13993003.01953-2017 · ExternalCitation · doi-reference
Epidemiology of bronchiectasis
10.1183/16000617.0091-2024 · ExternalCitation · doi-reference
Sinonasal disease among patients with primary ciliary dyskinesia: an international study
10.1183/23120541.00701-2022 · ExternalCitation · doi-reference
Effects of long-term use of macrolides in patients with noncystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials
10.1186/s12879-015-0872-5 · ExternalCitation · doi-reference
Prevalence and clinical implications of bronchiectasis in patients with overlapping asthma and chronic rhinosinusitis: a single-center prospective study
10.1186/s12890-021-01575-7 · ExternalCitation · doi-reference
Hypertonic saline in noncystic fibrosis bronchiectasis (Hyper-BRONCHI): an updated systematic review and meta-analysis
10.1186/s12890-026-04176-4 · ExternalCitation · doi-reference
Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST)
10.1186/s12931-019-1272-y · ExternalCitation · doi-reference
Systemic sclerosis and risk of bronchiectasis: a nationwide longitudinal cohort study
10.1186/s13075-023-03189-2 · ExternalCitation · doi-reference
Correlating Reiff scores with clinical, functional, and prognostic factors: characterizing noncystic fibrosis bronchiectasis severity: validation from a nationwide multicenter study in Taiwan
10.1186/s40001-024-01870-z · ExternalCitation · doi-reference
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I
10.1378/chest.113.5.1329 · ExternalCitation · doi-reference
Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of noncystic fibrosis bronchiectasis
10.1378/chest.12-1763 · ExternalCitation · doi-reference
Pneumothorax in cystic fibrosis
10.1378/chest.123.1.217 · ExternalCitation · doi-reference
Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease
10.1513/annalsats.201401-044fr · ExternalCitation · doi-reference
Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity
10.1513/annalsats.201507-472oc · ExternalCitation · doi-reference
Allergic bronchopulmonary aspergillosis and Aspergillus-related airway diseases in bronchiectasis: a narrative review
10.21037/jtd-2025-1548 · ExternalCitation · doi-reference
A systematic approach to the management of massive hemoptysis
10.21037/jtd.2017.06.41 · ExternalCitation · doi-reference
Predicting high risk of exacerbations in bronchiectasis: the E-FACED score
10.2147/copd.s121943 · ExternalCitation · doi-reference
Cystic Fibrosis-Related Diabetes (CFRD): overview of associated genetic factors
10.3390/diagnostics11030572 · ExternalCitation · doi-reference
Which is the best way to treat massive hemoptysis? A systematic review and meta-analysis of observational studies
10.3390/jpm13121649 · ExternalCitation · doi-reference
The phenotypes of asthma-bronchiectasis overlap: clinical characteristics and outcomes
10.4168/aair.2025.17.2.196 · ExternalCitation · doi-reference
Diagnosis and management of hemoptysis
10.5152/dir.2014.13426 · ExternalCitation · doi-reference
